Trial Profile

A clinical trial of AMP-101 in Dok-7 congenital myasthenic syndrome

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMP-101 (Primary)
Indications Congenital myasthenic syndromes
Focus Adverse reactions

Most Recent Events

10 Jan 2022 According to an Amplo Biotechnology media release, the company plans to begin clinical trials in Dok-7 congenital myasthenic syndrome in 2023.
10 Jan 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com